Review
Immunology
Jingyao Tu, Hang Liang, Chunya Li, Yongbiao Huang, Ziqi Wang, Xinyi Chen, Xianglin Yuan
Summary: Tumor immunotherapy has become a focus of research and treatment due to its effectiveness and fewer side effects compared to traditional treatments. However, the abnormal angiogenesis state of tumors can affect the efficacy of immunotherapy. The application of anti-angiogenesis drugs to normalize tumor vessels has shown promise in improving the effectiveness of immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Ruoyu Shen, Lijun Peng, Wentao Zhou, Ding Wang, Qi Jiang, Jian Ji, Fuqiang Hu, Hong Yuan
Summary: Abnormal tumor vasculature leads to malignant tumor microenvironment and affects tumor progression. We developed a nano-delivery system that sustains the release of anti-angiogenic agents to stabilize tumor vascular normalization, improving tumor perfusion and reversing abnormalities in the tumor microenvironment, ultimately inhibiting tumor progression.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Oncology
Mingshu Xiao, Yueli Shi, Sujing Jiang, Mengqing Cao, Weiyu Chen, Yun Xu, Zhiyong Xu, Kai Wang
Summary: Anti-angiogenesis therapy and immunotherapy are important strategies for tumor treatment. Nanomedicine has unique advantages in anti-angiogenesis therapy, such as targeted delivery and photothermal effects. This review provides a comprehensive overview on the use of nanomaterials in anti-angiogenesis therapy, focusing on the immunosuppressive effects of abnormal tumor vessels, targeting strategies of anti-angiogenesis nanomedicines, and the synergistic effects and molecular mechanisms when combined with immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Areez Shafqat, Mohamed H. Omer, Eman Nayaz Ahmed, Ali Mushtaq, Eman Ijaz, Zara Ahmed, Khaled Alkattan, Ahmed Yaqinuddin
Summary: This review focuses on the immunosuppressive effects of tumor angiogenesis and coagulation on the tumor microenvironment (TME). We summarize previous research efforts leveraging these observations and targeting these processes to enhance immunotherapy outcomes. Clinical trials have documented improved outcomes when combining anti-angiogenic agents and immunotherapy, but limitations and variable treatment outcomes have been noted. Understanding the key questions and directions for further research in this field is crucial for developing effective strategies to reprogram the TME in order to advance cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Naidong Zhang, Rongping Yin, Pei Zhou, Xiaomei Liu, Peng Fan, Long Qian, Li Dong, Chenglin Zhang, Xichen Zheng, Shengming Deng, Jiajie Kuai, Zhenhua Liu, Wen Jiang, Xiaohua Wang, Depei Wu, Yuhui Huang
Summary: Elevated levels of DLL1 in the TME promote long-term tumor vascular normalization, accumulation of CD8+ T cells, M1-like macrophage polarization, and increase the sensitivity of anti-CTLA4 therapy in resistant tumors.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Biochemistry & Molecular Biology
Hong-Tai Tzeng, Yu-Jie Huang
Summary: The abnormality of tumor vasculature creates a microenvironment that is not suitable for anti-tumor immune response and induces resistance to immunotherapy. Vascular normalization, achieved by anti-angiogenic approaches, reshapes the tumor microenvironment towards an immune-favorable one, enhancing the effectiveness of immunotherapy. The tumor vasculature serves as a potential pharmacological target to promote an anti-tumor immune response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Ping Yu, Yaru Wang, Dahai Yuan, Yunqin Sun, Shuang Qin, Tianye Li
Summary: The review provides a comprehensive overview of vascular normalization and its potential implications in ovarian cancer. The evidence suggests that vascular normalization therapy is a promising approach that can modify the tumor microenvironment, enhance anti-tumor immunity, and synergize with immunotherapy. This review contributes to the growing body of knowledge supporting the utilization of combination therapy as a promising treatment paradigm for ovarian cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Kai Wang, Qinhua Chen, Nanxin Liu, Jie Zhang, Xiaoyan Pan
Summary: One major issue in cancer treatment is resistance to chemotherapeutic drugs, often associated with abnormal blood vessels. Jain's vascular normalization theory has been applied effectively to drug-resistant tumor treatment. By using angiogenesis inhibitors, remodeling abnormal vessel structure and function can maximize the efficacy of chemotherapeutic drugs.
DRUG DISCOVERY TODAY
(2021)
Review
Cell Biology
Vinicio Melo, Edwin Bremer, John D. Martin
Summary: Immunotherapies modulate immune cells to target cancer cells, but the immunosuppressive nature of the tumor microenvironment (TME) limits their efficacy. TME normalization is a treatment strategy to reverse abnormalities in tumor blood vessels, resulting in enhanced antitumor immunity. Understanding how immunotherapies themselves normalize the TME is currently unclear.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Immunology
Raefa Abou Khouzam, Klaudia Brodaczewska, Aleksandra Filipiak, Nagwa Ahmed Zeinelabdin, Stephanie Buart, Cezary Szczylik, Claudine Kieda, Salem Chouaib
Summary: The environmental and metabolic pressures in the tumor microenvironment have a significant impact on tumor development, especially hypoxia-triggered events that promote growth, enhance resistance to the immune response, and stimulate angiogenesis. Normalizing tumor vasculature can restore integrity, increase perfusion, alleviate hypoxia, and reshape anti-tumor immunity, offering potential in achieving stable vascular normalization for mature and functional blood vessels.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Dipti Thakkar, Shalini Paliwal, Bhushan Dharmadhikari, Siyu Guan, Lillian Liu, Shreya Kar, Nikhil K. Tulsian, Joshua J. Gruber, Leah DiMascio, Konrad H. Paszkiewicz, Piers J. Ingram, Jerome D. Boyd-Kirkup
Summary: This study developed the first Fc-independent anti-VISTA antibody HMBD-002, which reverses VISTA-induced immune suppression by blocking the functional domain of VISTA. The antibody has a neutralizing, non-depleting effect, effectively inhibiting tumor growth and enhancing T cell activity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Jaeyun Jung, You Jeong Heo, Sehhoon Park
Summary: TMB status was analyzed using the TSO500 assay, and TMB-H was observed in 14.7% of the pan-cancer population. The study found that TMB-H patients had a higher response rate to anti-PD-(L)1 therapy, especially in gastric cancer, cholangiocarcinoma, melanoma, etc. Furthermore, patients with TMB >= 16 mut/Mb had prolonged survival after anti-PD-(L)1 therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Ashley B. B. Zhang, Khashayar Mozaffari, Brian Aguirre, Victor Li, Rohan Kubba, Nilay C. Desai, Darren Wei, Isaac Yang, Madhuri Wadehra
Summary: Glioblastoma, the most common malignant primary brain tumor, has a poor prognosis despite advancements in treatment. Angiogenesis, particularly involving vascular endothelial growth factor-A (VEGF-A), plays a critical role in the growth and invasion of glioblastoma cells. Bevacizumab, a medication targeting VEGF-A, has been approved for recurrent glioblastoma but has not significantly improved survival. Other agents with similar mechanisms of action have also shown unfavorable results. This review explores the current state and future potential of anti-angiogenesis therapeutic agents.
Review
Pharmacology & Pharmacy
Xu Xin Sun, Zeynab Nosrati, Janell Ko, Che-Min Lee, Kevin L. Bennewith, Marcel B. Bally
Summary: Immunotherapy has revolutionized cancer treatment, but there is a need for further improvements to enhance its positive benefits. Our team believes that combining drug delivery methods with the right small-molecule drugs can help double the overall survival rate for patients receiving immunotherapeutics.
Article
Immunology
Xiaojiao Sun, Zhuo Zhang, Zhiqi Wang, Ran Xie, Chuxiao Yi, Huiyu Liu, Xiaowei Chi, Tiancheng Li, Haitao Liu, Yi Han, Xiaocong Pang, Yimin Cui, Zhenming Liu
Summary: This study investigated the role of angiogenesis and remodeling in the tumor immune microenvironment in pan-cancer, and found that high AR score was associated with worse prognosis and immune cell infiltration in certain tumors. Targeting AR genes may activate the immune microenvironment and enhance the efficacy of immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Yuwen Zhu, Yan Guo, Yujia Xue, Anqi Zhou, Ying Chen, Yifei Chen, Xiulian Miao, Fangqiao Lv
Summary: BRG1 plays an important role in HSC-myofibroblast transition and targeting it could be a reasonable strategy for liver fibrosis intervention.
Article
Medicine, Research & Experimental
Liu Ye, Beibei Liu, Jingling Huang, Xiaolin Zhao, Yuan Wang, Yungen Xu, Shuping Wang
Summary: Doublecortin-like kinase 1 (DCLK1) is a significant prooncogenic factor that is strongly associated with the malignant progression and clinical prognosis of various cancers. DCLK1 plays important roles in stem cell marker regulation, tumor cell reprogramming, and immune evasion. However, the exact biological functions of DCLK1, especially the disparities between its alpha- and beta-form transcripts in cancer progression, remain ambiguous.
Article
Medicine, Research & Experimental
Jiahui Yang, Xiaoyu Chen, Tianjing Liu, Yongyan Shi
Summary: This article reviews the role of bile acids in necrotizing enterocolitis (NEC) and their potential therapeutic value. The dysregulation of bile acids is associated with intestinal injury, and inflammatory factors in the liver also play a crucial role in regulating bile acid transport. The bile acid metabolic pathway is important for regulating intestinal microbiota, cell proliferation, and barrier protection.
Review
Medicine, Research & Experimental
Zhenzheng Zhu, Yuemiao Xu, Yuwei Xia, Xinru Jia, Yixin Chen, Yuyue Liu, Leyin Zhang, Hui Chai, Leitao Sun
Summary: Bile acid, as the final product of cholesterol breakdown, plays a complex regulatory and signaling role in human metabolism. Research suggests that it has the potential to enhance metabolism and regulate chronic metabolic diseases through various pathways. The interaction between bile acid and gut microbiota is also of great significance.
Article
Medicine, Research & Experimental
Xin He, Hong-Xu Zhou, Xian Fu, Kai-Di Ni, Ai-Zhi Lin, Ling-Tong Zhang, Hou-Hua Yin, Qing Jiang, Xue Zhou, Yi-Wen Meng, Jun-Yan Liu
Summary: DON exposure causes an increase in deoxycholic acid (DCA), which contributes to intestinal injury. DCA may be a potential therapeutic target for DON enterotoxicity.
Article
Medicine, Research & Experimental
Zhitao Wang, Heng Ma, Abdul Nasir, Sufang Liu, Zhisong Li, Feng Tao, Qian Bai
Summary: This study reveals the involvement of TET1-mediated epigenetic regulation in chronic TMJ pain through trigeminal TNF alpha signaling.
Article
Medicine, Research & Experimental
Lu Yu, Hao Ran, Yaru Lu, Qian Ma, Huan Huang, Weibin Liu
Summary: This study found that the HIF-1 alpha inhibitor BAY 87-2243 can alleviate the symptoms of the Experimental Autoimmune Myasthenia Gravis (EAMG) inflammation model. BAY 87-2243 can restore the balance of CD4(+)T cell subsets, reduce the production of pro-inflammatory cytokines, and act as both an immune imbalance regulator and anti-inflammatory.
Article
Medicine, Research & Experimental
Alex Peralvarez-Marin, Montse Sole, Judith Serrano, Alice Taddeucci, Belen Perez, Clara Penas, Gemma Manich, Marcel Jimenez, Pilar D'Ocon, Francesc Jimenez-Altayo
Summary: This study provides the first evidence that TRPV2 channels may modulate vascular tone by balancing opposing inputs from the endothelium and smooth muscle, leading to net vasodilation. The amplification of TRPV2 channel-induced activity by NO emphasizes the pathophysiological relevance of these findings.
Article
Medicine, Research & Experimental
Amin Ullah, Jing Zhao, Jiakun Li, Rajeev K. Singla, Bairong Shen
Summary: Gastric cancer is the fifth-most prevalent and second-most deadly cancer worldwide. Late onset of symptoms makes early detection important. CXC chemokines play an important role in the pathological process of gastric cancer, but their exact role in diagnosis and prognosis is not fully understood. Inhibiting CXC chemokines shows promise as a targeted therapy.
Article
Medicine, Research & Experimental
Menna S. Zeyada, Salma M. Eraky, Mamdouh M. El-Shishtawy
Summary: The current study demonstrates the prophylactic and antifibrotic effects of Trig against BLM-induced PF by targeting multiple signaling pathways. The combination of Trig and Pirf may be a promising approach to enhance Pirf's anti-fibrotic effect.